RESEARCH HANDBOOK ON THE PROTECTION OF INTELLECTUAL PROPERTY UNDER QTO%RULES VOLUME IPDF电子书下载

查看更多关于的内容

PART I HISTORY, INTERPRETATION AND PRINCIPLES 3

1. Why IPR issues were brought to GATT: a historical perspective on the origins of TRIPS&Charles Clift 3

2. Developing countries in the global IP system before TRIPS: the political context for the TRIPS negotiations&Carolyn Deere-Birkbeck 22

3. Minimum standards vs. harmonization in the TRIPS context: the nature of obligations under TRIPS and modes of implementation at the national level in monist and dualist systems&Denis Borges Barbosa 52

4. Enhancing global innovation policy: the role of WIPO and its Conventions in interpreting the TRIPS Agreement&Graeme B. Dinwoodie and Rochelle C Dreyfuss 110

5. The objectives and principles of the TRIPS Agreement&Peter K. Yu 146

6. Mainstreaming the TRIPS and human rights interactions&Xavier Seuba 192

7. The TRIPS Agreement and intellectual property rights exhaustion&Luis Mariano Genovesi 216

8. Intellectual property rights and competition policy&Beatriz Conde Gallego 226

9. Intellectual property rights in free trade agreements: moving beyond TRIPS minimum standards&Pedro Roffe, Christoph Spennemann and Johanna von Braun 266

PART II SUBSTANTIVE RIGHTS 319

10. Limits, limitations and exceptions to copyright under the TRIPS Agreement&P. Bernt Hugenholtz 319

11. Copyright in TRIPS and beyond: the WIPO Internet Treaties&Ruth L. Okediji 343

12. The protection of 'related rights' in TRIPS and the WIPO Performances and Phonograms Treaty&Owen Morgan 379

13. Marks for goods or services (trademarks)&Annette Kur 408

14. Unresolved issues on geographical indications in the WTO&Kasturi Das 448

15. No lemons' no more: a sketch on the 'economics' of geographical indications&Dwijen Rangnekar 515

16. Exploring the flexibilities of TRIPS to promote biotechnology in developing countries&Graham Dutfield, Lois Muraguri and Florian Leverve 540

17. Compulsory licensing of patented pharmaceutical inventions: evaluating the options&Jerome H. Reichman 589

18. The Doha Declaration and access to medicines by countries without manufacturing capacity&S.K. Verma 623

19. Disease-based limitations on compulsory licenses under Articles 31 and 31bis&Kevin Outterson 673

20. The protection of semiconductor chip products in TRIPS&Thomas Hoeren 698

21. Data exclusivity for pharmaceuticals: TRIPS standards and industry's demands in free trade agreements&Carlos M. Carrea 713

Index 729

查看更多关于的内容